Adaptimmune Therapeutics 2018 Annual Report 10-K

Adaptimmune Therapeutics plc annual report for fiscal year 2018 detailing operations of SPEAR T-cell therapy development programs including ADP-A2M10, ADP-A2M4, and ADP-A2AFP candidates. Report covers clinical development progress, manufacturing capabilities, GSK collaboration, regulatory matters, and risk factors in the biopharmaceutical sector.